Method for diagnosing estrogen- and progesteron-dependent genitalia abnormalities |
||||||||||||||||||||||||||
|
IPC classes for russian patent Method for diagnosing estrogen- and progesteron-dependent genitalia abnormalities (RU 2312354):
Method for selecting female patients with the syndrome of "empty" follicles for carrying out ecf and et program with donor oocytes / 2309411
It is necessary to determine the content follicle-stimulating hormone (FSH) in follicular liquid in female patients with the syndrome of "empty" follicles (SEF), insulin-like growth factor (IGF-1) and human chorionic gonadotropin (hCG) to calculate differential value (DV) by the following formula: DV=exp(IV)/1+expIV), where IV - intermediate variable calculated by the following formula: IV=1.821+1×FSH-0.18×IGF-1+0.136×hCG, Exp - exponential function and at DV being below 0.5 the development of SEF is of absolute nature and a female patient should be recommended to have donation of oocytes, at DV being above 0.5 the development of SEF is of sporadic character and a patient should be recommended to undergo repeated curative ECF cycles. The innovation enables to elaborate the method for predicting the procedure of extracorporal fertilization and embryo transfer.
Method for diagnosing abdominal cavity organ injuries / 2308872
Method involves carrying out video laparoscopic examination. Hemorrhagic content volume being less than 150 ml with no hemolysis, hemorrhagic content pH is determined. The pH value being less than 6.6, aimed laparoscopic examination starts from the stomach; pH being equal to 6.7-6.9 - from gallbladder; pH 7.0-7.1 - from the intestine; pH 7.2-7.4 - from the spleen; pH 7.5-7.8 - from the liver.
Method for predicting ectopia of uterine cervix in females of reproductive age / 2306569
It is necessary to monitor the content of follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), progesterone (P) in blood serum on the 7th, 14th, 21st d of menstrual cycle due to immunoenzymatic technique. At FSH values ranged 4.98-5.78 IU/l on the 7th d of menstrual cycle, 9.88-11.52 IU/l on the 14th d of menstrual cycle, 6.91-7.85 IU/l on the 21st d of menstrual cycle, LH ranged 5.11-5.75 mIU/l on the 7th d of menstrual cycle, 11.7-12.23 mIU/l on the 14th d of menstrual cycle, 5.66-7.18 mIU/l on the 21st d of menstrual cycle, E2 ranged 41.28-44.93 pg/ml on the 7th d of menstrual cycle, 134.78-143.92 pg/ml on the 14th d of menstrual cycle, 98.91-109.29 pg/ml on the 21st d of menstrual cycle, Pranged 1.02-1.53 nM/l on the 7th d of menstrual cycle, 1.31-1.79 nM/l on the 14th d of menstrual cycle, 6.80-7.16 nM/l on the 21st d of menstrual cycle one should diagnose the ectopia of uterine cervix in females of reproductive age.
Method for predicting hollow follicles syndrome / 2302639
Method involves determining luteinizing hormone concentration, follicle-stimulating hormone concentration, estradiol concentration, progesterone concentration, testosteron concentration in blood according to program ECO during the first days of menstrual cycle before superovulation stimulation. Prognostic criterion is calculated using the obtained data PC=ехр(K)/(1+ехр(K)), where Ехр(х) is the exponential function, K is the intermediate variable calculated from formula K=0.423+0.02хLG- 0.189хfSG-0.421хE2+0.3хP1-0.987хТs, where LG is the luteinizing hormone concentration in blood, IU/l; fSG is the follicle-stimulating hormone concentration in blood, IU/l; E2 is the estradiol concentration in blood, nmole/l; P1 is the blood progesterone concentration, nmole/l; Ts is the testosteron concentration in blood, ng/ml. Empty follicles syndrome is predicted using calculated PC value less than 0.5.
 Method for predicting clinical mammary gland carcinoma course / 2300111
Method involves determining tumor cells percent and estimating receptor color in semi-quantitative way. Positive cells proportion is recorded and reaction intensity is determined from formula H=3xA+2xB+1xC, where A is the intensively stained nuclei percent; B is the moderately stained nuclei percent; C is the mildly stained nuclei percent. Receptor distribution is determined in addition in tumor units of mammary gland carcinoma. Sites of positive and negative expression and various expression intensity sites being found, the expression is considered to be heterogeneous. Uniform receptor distribution being observed in the tumor irrespective of staining intensity degree, the expression is considered to be homogeneous. Homogeneous steroid hormone receptor expression being observed in tumor, favorable clinical disease treatment course is to be predicted. When heterogeneous, the prognosis is unfavorable.
Method for detecting extracranial metastases in metastatic brain injury patients / 2300110
Method involves determining cortisol hormone concentration in cerebral metastasis-ill patient blood prior to treatment beginning. Its concentration being found within the limits of 54.0 to 130.0 nmole/l, metastatic lesion foci are predicted to be available in other internal organs and tissues.
Method for predicting cerebral metastasis lesion foci in metastatic brain injury patients / 2300109
Method involves determining thyroxin hormone concentration in cerebral metastasis-ill patient blood prior to treatment beginning. Its concentration being found within the limits of 68.0-115.0 nmole/l, 1 to 3 metastatic lesion foci are predicted to be available. The concentration being from 38.0 to 50.0 nmole/l, more than 4 p metastatic lesion foci are predicted to be available.
Method for predicting extracranial metastases development in patients having metastases in brain / 2297005
Method involves determining adrenal glands cortex hormone cortisol content in blood. At its level below the bottom border of the norm making from 260.0 up to 450.0 nmole/l, within the limits of cortisol concentration fluctuations from 70.0 to 240.0 nmole/l, extracranial metastases development are predicted to occur in 1-3.5 months after primary examination.
Method for predicting physical growth and development of small children / 2291444
Method involves determining triiodothyronine content in peripheral blood serum of children of the second half-year of life having perinatal central nervous system injury manifestations and no signs of hypothyroidism. The value being equal to 0.69±1.34 ng/ml, the children are predicted to have small height to the third year of life.
 Method for carrying out monitoring of diabetes mellitus patients state and neurological and vascular complications development / 2291437
Method involves determining immune reactivity of blood serum with respect to insulin, to anti-insulin antibodies or their antigen-binding fragments, to anti-anti-insulin antibodies binding the antibodies to insulin and antigens to growth factor or their antigen-binding fragments and ANCA antigen. Blood serum immunoreactivity increase with respect to parameters under measurement relative to norm is used for determining diabetes mellitus neurological and vascular complications development.
 Method for determining substances transport intensity changes in prevailing directions between blood and non-mineralized organs / 2297001
Method involves introducing radioisotope to animals and further repeatedly determining radioisotope inclusions percent in blood and in and in non-mineralized organs in given time intervals, calculating relative radio-activity RRA for an animal examined at each time as ratio between radioisotope inclusions percent in non-mineralized organs to radioisotope inclusions percent in blood. Then transport intensity is determined in prevailing directions in each examination time by applying RRA difference factor (DFRRA), calculated as difference between the subsequent and previous RRA values. The received values of DFRRA factor changes are interpreted in terms of intensity time fluctuations and radioisotope transport direction for each organ.
Method for detecting toxic action of oral mucosal interferonotherapy / 2288474
One should daily introduce into oral cavity of inbred mouse BALB/c for about 3-5 d an olive-shaped melted edge of capron fish line of 0.5-2.0 mm diameter impregnated with glycerol-containing preparation of recombinant interferon-α, containing 104-106 IU/ml recombinant human interferon-α, then in a dead mouse it is necessary to determine against an intact mouse the morphofunctional state of hepatocytes, enterocytes, lymphoid tissue of regional lymph nodes to evaluate: the absence of toxic action of oral mucosal interferonotherapy in case of no degenerative alterations in hepatocytes, enterocytes, lymphoid tissue of regional lymph nodes in inbred mouse BALB/c subjected to oral mucosal interferonotherapy; the presence of toxic action of oral mucosal interferonotherapy at availability of degenerative alterations of hepatocytes and/or enterocytes, and/or lymphoid tissue of regional lymph nodes in inbred mouse BALB/c after oral mucosal interferonotherapy. The innovation increases information value of the method suggested.
 Identification of transgenic dna sequences in plant material and products made of the same, oligonucleotide kit and bioarray therefor / 2270254
Invention relates to method for detection of typical marker foreign DNA sequences, usable in plant modification, in transgenic plant materials and products made of the same. Claimed identification method includes carrying out of multiplex polymerase chain reaction on the base of DNA isolated from tested material followed by hybridization of fluorescent labeled reaction products on specialized bioarrays. Hybridization data are registered by control and program complex and identification of foreign genes and regulatory zones thereof in tested material is carried out, and obtained results are quantitatively interpreted.
Method for detecting immunoreactive compounds / 2268471
The present innovation deals with one-stage detection of a bound analyte with a conjugate consisted of an analyte-stereospecific compound (anti-analyte) being covalently conjugated with suspensoid particles of water-insoluble dyestuffs, as coumassi R-250, and/or acridine yellow, and/or acridine orange, and/or 2.4-nitrodiphenyl hydrazine, and/or fluorescein. Application of an anti-analyte with a colored suspensoid label in technology for obtaining conjugates for analysis of one-stage covalent binding leads to considerable simplification of synthesis procedure, increased economy, and reproducibility and higher sensitivity of detection systems. Thus, the innovation enables to improve sensitivity and reliability of stereospecific analysis and optimization of technology to obtain reagents applied in this process being necessary for detection (stereospecific conjugates).
 The method of determining the direction of transport and metabolic rate between mineralized tissue and contacting the biological fluid / 2242007
The invention relates to medicine and can be used in dentistry, trauma, radiology, biochemistry and pathophysiology
 The method for determining the level of circulating autoantibodies in biological fluids / 2240561
The invention relates to medicine, in particular to immunology, and can be used for the diagnosis of autoimmune process
 Method of imaging cell death in the body of a mammal subject in vivo / 2228765
The invention relates to medicine, in particular to radiology
The method of therapeutic effects on the body / 2228531
The invention relates to medicine, namely to immunology, and can be used for the treatment of diseases associated with a dysfunction of the immune system
 The reagent for diagnosing infections caused by puumala virus / 2218571
The invention relates to diagnostics of virus
 Labeled luciferase antibody and a method thereof, a method of performing analysis on specific binding and set for use in the analysis of the specific binding / 2199125
The invention relates to biotechnology, relates to a method of conjugating luciferase with chemical particle, in particular antibody, providing (a) mixing luciferase with one or more components, such as D-luciferin, magnesium ions and ATP, and (b) carrying out the reaction of covalent binding between luciferase and linking reagent using covalently bonding agent, where D - luciferin, magnesium ions and/or adenosine triphosphate present in a quantity sufficient to protect the luciferase activity from inhibition of covalently binding agent
Method for detecting immunoreactive compounds / 2268471
The present innovation deals with one-stage detection of a bound analyte with a conjugate consisted of an analyte-stereospecific compound (anti-analyte) being covalently conjugated with suspensoid particles of water-insoluble dyestuffs, as coumassi R-250, and/or acridine yellow, and/or acridine orange, and/or 2.4-nitrodiphenyl hydrazine, and/or fluorescein. Application of an anti-analyte with a colored suspensoid label in technology for obtaining conjugates for analysis of one-stage covalent binding leads to considerable simplification of synthesis procedure, increased economy, and reproducibility and higher sensitivity of detection systems. Thus, the innovation enables to improve sensitivity and reliability of stereospecific analysis and optimization of technology to obtain reagents applied in this process being necessary for detection (stereospecific conjugates).
|
FIELD: medicine. SUBSTANCE: method involves determining estradiol- and progesterone receptors concentration in mononuclear cells fraction of peripheral blood. The value being greater than 210 and 2050 receptors per cell, estrogen- and progesteron-dependent genitalia abnormalities are diagnosed, respectively. EFFECT: high diagnosis accuracy; no biopsy needed. 1 tbl
The invention relates to medicine, in particular to the gynecologist. The increase in the number of receptors for estradiol and progesterone in a modified tissue indicates hormonal dependence of the pathological process. The most socially significant hormone-dependent disorders of the genitals at the present time can be considered as endometrial hyperplasia, endometriosis, uterine fibroids (Serov V.N. et al. Gynecological endocrinology. Moscow: HONEY-presentors, 2004, 520 S.). Modern diagnosis of hormone-dependent States genitalia includes: ultrasound (Manukhin IB et al. Clinical lectures on gynecology. - M: Honey. information Agency, 2001, 243 C.) registers a lesion, for example, the thickness of the endometrium. According to manukhina EB, normal endometrium in the phase of secretion correspond to values of 9.8±2.1 mm, endometrial hyperplasia with 15.4±10,4 mm, adenocarcinoma of the endometrium - 20,12±2,04 mm. This method determines only a lesion in the tissue, but does not allow to judge about their hormonal dependency. To confirm the preliminary diagnosis based on the data of the M-ECHO (ultrasound), use: histological study of biopsy material. It allows you to diagnose specific morphological nosology. However, this method does not resolve the question of the hormone is through according to the pathological process. - Definition of gonadotropins and sex steroids in peripheral blood (Smetnik VP, Tumilovich G. non-operative gynecology. - M: Honey. information Agency, 2000, 591 C.) is necessary to evaluate hormonal diseases, which often initiates and accompanies the pathological process. Hormonal change (for example, absolute or relative from hyperestrogenemia) the patient is indirect confirmation of the hormonal dependence of the pathological process, but does not reflect the state of the receptor status of the diseased tissue. Closest to the proposed method for the diagnosis of estrogen - and progesteronepositive pathology of the genitals is to determine the level of receptors for estradiol and progesterone in the biopsy (V. Krasnopolsky et al. "Service sex steroids in hyperplastic endometrium in women of late reproductive age" / J. Ross. Bulletin of the obstetrician-gynecologist. - M.: mediasphere, 2005, volume 5, No. 2, p.7-9). The disadvantage of this method is its invasiveness, namely fence biopsy of the diseased tissue. The objective of the invention is a non - invasive method for the diagnosis of estrogen - and progesteronepositive pathological process genitals. The problem is solved by a method for the diagnosis of estrogen - and progest rosavinia pathology of the genitals namely, that determine the number of receptors for estradiol and progesterone in the mononuclear fraction of peripheral blood cells and an increase of more than 210 and 2050 receptors per cell, respectively diagnosed with estrogen - or progesteronelike pathology. The claimed invention is not obvious to professionals working in the field of endocrinology gynecology. Method. Mononuclear cells peripheral blood allocate the standard method [Boyum A. Separation of leukocytes from blood and bone marrow // Scand. J. Clin. Lab. Investig. - 1968. - Vol.21 - Suppl. 97. p.1-9] from heparinised blood (7-10 IU of heparin/ml) with modifications. Blood diluted with a physiological solution (pH of 7.2) in the ratio 1:2. Diluted saline blood (5 ml) layer on warmed to room temperature ficoll (Pharmacia Fine Chemicals, Sweden, density 1, 077 g/ml, 3 ml centrifuge tube and centrifuged at 400g for 30 min, 4° [Kheifets LB, Abalkin, VA Separation of blood corpuscles of man //J. lab. business, 1973. - 10. - s-581]. The interphase select a sterile glass pipette and the resulting mononuclear cell fraction is washed three times colorless Hanks solution (cell resuspending in a tenfold volume of Hanks solution and centrifuged 5 minutes at 250 g). The last residue raise in 1 ml of medium and counted in the camera Goryaeva. After the account diluted with medium to a cell concentration of 500 million/100 μl. Cell viability, determined by the method of staining with Trifanova blue (lang E.G. Stimulation of lymphocytes // M.: Medicine, 1976. - 288 S.)amounted to 96%. The method of determining the receptors of progesterone and estradiol in mononuclear blood cells based on the known method of determining these receptors in the fraction of plasma membrane of bioerosion [Bassaleg. The steroid hormone receptors in human tumors. M, Medicine, 1987, str-202]. Time and concentration parameters of the saturation binding labels are chosen experimentally. For the quantitative determination of progesterone receptor and estradiol levels in mononuclear cells prepared sterile plastic tablet (96 round-bottom wells): on all working wells contribute 10 ál alcohol solution3H-progesterone or3H-estradiol (Amersham GB) of receipt in the incubation medium final concentration of 20 and 5 nm, respectively. In order to inhibit specific binding of steroid use two hundredfold excess of unlabeled progesterone and diethylstilbestrol respectively (Merck, Germany), which in an alcohol solution contribute to the wells according to the standard scheme. 200-fold excess of dexamethasone (Merck, Germany) is added to the working wells to inhibit cross-linking of glucocorticoids with receptor progester is on. After making holes alcohol solutions of these steroids alcohol is evaporated in a stream of nitrogen. 30 minutes before incubation in the wells contribute 50 ál environment Hanks. All the prepared wells contribute 50 μl of the suspension of mononuclear cells (500 million cells/100 µl) and incubated for 60 minutes for progesterone receptor, 30 minutes to determine receptor estradiol at room temperature. To separate the unbound label resuspendable cells filtered through glass filters (Whatman Glass Micro Fiber Filter GF/B - 25 mm dia.), who washed 100-fold excess of ice-cold Hanks and placed in scintillation vials. After evaporation filters pour 5 ml of scintillation fluid and after 60 minutes radiometric. All studies conducted in triplets. Counting specific binding produced by the formula: [(T-NSB)·k/n]·N where T is the total binding, NSB - non-specific binding, n is the number of cells in a hole, k is the conversion factor cpm in femtomole3H-steroid, N is the number of Avogadro. The following examples illustrate the method according to the invention. Example 1. Patient B., 42 years aimed at NPO MONIII 11.03.04, with a diagnosis of recurrent hyperplasia and endometrial polyp to determine further tactics of treatment. Hyperprolinemia. History 2 separate diagnostic curettage (WFD) 05.03 GI in 10.03, These histological conclusion: glandular endometrial hyperplasia and glandular fibrous polyp of endometrium. The diagnosis of recurrent endometrial hyperplasia was confirmed based on clinical data and results of ultrasound on the 7th day of cycle: M-echo 12 mm and the bottom of the uterus polyp with a diameter of 10 mm 13.04.04 were hysteroscopy and WFD. The endometrium is the late stage of secretion with elements basal and microgenesis hyperplasia. Fragments of fibro-glandular polyp of endometrium. The parameters of the reception of female sex steroids in the mononuclear fraction of peripheral blood cells and endometrial biopsy were conducted in parallel, while the blood was taken from the cubital vein of the patient immediately prior to scraping. When determining the number of receptors for estradiol and progesterone in mononuclear cells of peripheral blood obtained the following values: for estradiol - 875 Retz/cage and progesterone - 2541 Retz/cage, allowing us to diagnose estrogen - and progesteronelevel pathological process. In the biopsy of the endometrium obtained during diagnostic curettage, the level of cytosolic receptors estradiol and progesterone 24.1 and 25.9 fmol/mg protein cytosol respectively. Thus, the results of the receptor profile and endometrial biopsy confirmed is received by us, in the study of MNCs, data on the hormonal dependence of endometrial hyperplasia in a given patient. Based on the above data was scheduled and held anti-hormonal therapy Duphaston 20 mg/day with 5 for 25 day of a cycle of 6 months with a positive effect. During therapy, and 12 months after relapse was not. Example 2. Patient K., 48 years old, came to the Department of gynecological endocrinology with complaints hyperelementary and repeated dysfunctional uterine bleeding within 3 years. History about menorrhagia residence produced 2 of the WFD. The histological conclusion: glandular hyperplasia with symptoms of chronic endometritis. Domiciliary received hormonal therapy norcolut and primaluna at a dose of 10 mg with 5 for 25 day of a cycle - without effect. The year before our study received Duphaston 20 mg per day with 16 for 25 day of a cycle - no effect after the abolition of re-treatment of menorrhagia, and therefore was sent to MONIYA. When ultrasound endometrial thickness (M-echo) was 13 mm In the left ovary is defined retention cyst with a diameter of 3.9 see the Conclusion: endometrial hyperplasia, adenomyosis, uterine myoma of the small sizes. The patient made a separate diagnostic curettage under control hysteroscopy. Histology the ical conclusion: simple glandular hyperplasia of the endometrium with signs of chronic inflammation. Studies: receptor profile mononuclear fraction of peripheral blood and biopsy of the endometrium by the methods described in example 1. Results: receptors for estradiol and progesterone - 160 and 0 Retz/cell in MNCs respectively; 7.6 and 0 fmol/mg protein cytosol endometrial biopsies, respectively. Therefore, the pathological process in the endometrium is not gormonzavisimym. The patient was proposed and carried out an alternative method of treatment is panhysterectomy. We have shown that the parameters of the receptor profile of estradiol-17β and progesterone in the mononuclear fraction of cells (MNCs) peripheral blood match (closely and positively correlated r=0,77 and 0.9, respectively) with the same parameters of the endometrium of patients with hyperplasia (table 1).
Given the strong positive correlation between the level of sex steroid receptors in the OLS and the cytosol of the biopsy of the endometrium of patients with hyperplasia, consider the legitimate use of the reception parameters of estradiol and progesterone in the mononuclear fraction of peripheral blood cells to assess the hormonal dependence of the pathological process in the endometrium. A comparative analysis of the level of sex steroid receptors in the OLS and the cytosol endometrial hyperplasia showed that thresholds hormonal dependence can be considered as the number of receptors for estradiol and progesterone in OLS 210 and 2050 Retz/CL (corresponding to ≈10 fmol receptor estradiol and progesterone in endometrial cytosol, respectively). When diagnosing estrogen - and progesteronepositive pathology 59 patients was confirmed by its ability to use for diagnostic purposes and its high is echnosti. Method for the diagnosis of estrogen - and progesteronepositive pathology genitals by examining the content of the receptors estradiol and progesterone metabolites in biological material, characterized in that the support of receptors in mononuclear fraction of peripheral blood cells and when the value of more than 210 and 2050 receptors per cell, respectively diagnosed with estrogen - and progesteronelike pathology genitals.
|
|||||||||||||||||||||||||